Please login to the form below

Not currently logged in
Email:
Password:

Shire picks Bayer's Flemming Ornskov as new head

He will succeed Angus Russell who is retiring next year

Shire Flemming OrnskovAngus Russell is stepping down as chief executive of the Dublin-based specialty pharmaceutical company Shire next year.

His replacement will be Flemming Ornskov, who is currently chief marketing office and global head of strategic marketing (general and specialty medicine) at Bayer.

Ornskov will join the company on January 2, 2013, as chief executive designate, spend time with all three Shire businesses and will have a special focus initially on the specialty pharmaceuticals business.

He will be based at Shire's US offices outside Philadelphia, during this period, following after which he will become CEO on April 30, 2013.

Flemming Ornskov said: “Shire stands out in the industry. I'm motivated and inspired by the company's vision and excited to bring the combination of my medical, multi-national and entrepreneurial business background to lead Shire to the next phase of its development.”

Prior to his time at Bayer, Ornskov was global president, pharmaceuticals and OTC at Bausch & Lomb. Before this he served as CEO at both Lifecycle Pharma and US biotech Ikaria, and worked at Merck & Co and Novartis.

His selection as CEO came as part of Shire's search for a new president for its specialty pharmaceuticals business after the resignation in April of Michael Kola. A process the company intended to yield a potential successor for Angus Russell.

Russell will retire in 2013 after 13 years with Shire and a full 32 years of working in the pharmaceutical industry.

Shire chair Matthew Emmens said: “Angus led the company through a period of extraordinary growth and was instrumental in establishing a winning strategy and a powerful and compelling culture. We wish him and his family well in his retirement.”

26th October 2012

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude

We are experts in customer engagement. A strategic multichannel marketing and customer experience agency, specialising in pharmaceuticals, medical devices, and...

Latest intelligence

More of the same: The importance of strategic communications planning for biosimilar entry
GCI Health's Hannah Morris considers the importance of strategic communications planning for biosimilar entry, a market anticipated to deliver between €8-26bn in savings across the European Union by 2020....
Online Physician Communities
How can pharma realise the power of digital?
Firstly, by making it owned and driven by the most senior leadership team in the business...
Remapping the market: Does Pharma's global model need a shake up?
For patients, carers and professionals, wherever they are in the world, digital technology is inherent in their everyday lives. Digital is, so to speak, a global language. The success of...